Factors associated with distant recurrence (DR) risk in patients (pts) with HR+/HER2-early breast cancer (EBC): a machine learning (ML) model-based analysis using real-world (RW) data

被引：0
|
作者：
Sparano, J. A. [1 ]
Lustberg, M. B. [2 ]
de Nonneville, A. [3 ]
Bachelot, T. [4 ]
Santa-Maria, C. A. [5 ]
Blyuss, O. [6 ]
Fasching, P. A. [7 ]
Brezden-Masley, C. [8 ]
Park, Y. H. [9 ]
Akdere, M. [10 ]
Ye, F. [11 ]
Pattipaka, T. [10 ,12 ]
Manneni, V. R.
Kurz, C. [13 ]
Castro, P. Dominguez [14 ]
Howard, F. M.
机构：
[1] Tisch Canc Inst, T Canc Inst, New York, NY 10029 USA
[2] Yale Univ, Sch Med, Sch Med, New Haven, CT USA
[3] Aix Marseille Univ, Inst Paoli Calmettes, CRCM, CNRS,INSERM,CRCM, Marseille, France
[4] Ctr Leon Berard, Dept Med Oncol, Lyon, France
[5] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Breast & Gynecol Malignancies Grp, Baltimore, MD USA
[6] Queen Mary Univ London, Wolfson Inst Populat Hlth, Ctr Prevent Detect & Diag, London, England
[7] Friedrich Alexander Univ Erlangen Nuremberg, Univ Hosp Erlangen Comprehens Canc Ctr Erlangen EM, Erlangen, Germany
[8] Univ Toronto, Mt Sinai Hosp, Fac Med, Div Med Oncol & Hematol, Toronto, ON, Canada
[9] Sungkyunkwan Univ, Sch Med, Div Hematol Oncol, Div Hematol Oncol,Sch Med, Seoul, South Korea
[10] Novartis Pharm AG, Basel, Switzerland
[11] Novartis Pharmaceut, E Hanover, NJ USA
[12] Novartis Healthcare Pvt Ltd, Hyderabad, Telangana, India
[13] Novartis Pharma GmbH, Munich, Germany
[14] Novartis Ireland, Dublin, Ireland
来源：
BREAST | 2025年 / 80卷
关键词：
D O I：
10.1016/j.breast.2025.104097
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P258
引用
收藏
页数：2
相关论文
共 36 条
  • [31] PATIENT CHARACTERISTICS, DIAGNOSTIC TESTING AND TREATMENT PATTERNS IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+, HER2-), NODE-POSITIVE, HIGH-RISK EARLY BREAST CANCER (EBC) IN ITALY: A REAL-WORLD STUDY
    Buzzoni, C.
    Tamma, A., V
    Giovannitti, M.
    Brown, J.
    Williams, R.
    Rider, A.
    Sanderson, I
    VALUE IN HEALTH, 2022, 25 (01) : S264 - S264
  • [32] Analysis of real-world (RW) data for metastatic breast cancer (mBC) patients (pts) with somatic BRCA1/2 (sBRCA) or other homologous recombination (HR)-pathway gene mutations (muts) treated with PARP inhibitors (PARPi).
    Batalini, Felipe
    Madison, Russell
    Pavlick, Dean C.
    Sokol, Ethan
    Snow, Tamara
    Sondhi, Arjun
    Frampton, Garrett M.
    Jenkins, Colby
    Garber, Judy Ellen
    Wulf, Gerburg M.
    Venstrom, Jeffrey Michael
    Tung, Nadine M.
    Castellanos, Emily
    Schrock, Alexa Betzig
    McGregor, Kimberly
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] Genome-wide DNA methylation analysis identifies novel biomarkers associated with risk of relapse beyond oncotype DX recurrence-score risk assessment within HR+/HER2-early-stage breast cancer patients
    Fuentes-Antras, Jesus
    Garcia-Barberan, Vanesa
    Costa-Fraga, Nicolas
    Moreno, Fernando
    Bao-Caamano, Aida
    Rodriguez-Casanova, Aitor
    Sa, Alfonso Lopez de
    De Luna, Alicia
    Lopez-Cade, Igor
    Ramirez-Ruda, Carmen
    Pascual, Alejando
    Perez-Segura, Pedro
    Gyorffy, Balazs
    Ocana, Alberto
    Diaz-Lagares, Angel
    Garcia-Saenz, Jose Angel
    CANCER RESEARCH, 2022, 82 (04)
  • [34] Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+early-stage breast cancer patients who received trastuzumab: Evidence from a real-world study with long-term follow-up
    Ju, Jie
    Gao, Song-Lin
    Wang, Jia-Yu
    Sang, Die
    Kang, Yi-Kun
    Wang, Xue
    Yue, Jian
    Shuai, You
    Qi, Yi-Xin
    Yuan, Peng
    THORACIC CANCER, 2024, 15 (06) : 439 - 447
  • [35] TREATMENT PATTERNS AND CLINICAL OUTCOMES AMONG PATIENTS RECEIVING CDK4/6 INHIBITORS FOR HR+/HER2ADVANCED/METASTATIC BREAST CANCER IN A SINGLE-CENTRE, CANADIAN REAL-WORLD SETTING USING AI-EXTRACTED DATA
    Moulson, Ruth
    Feugere, Guillaume
    Moreira-Lucas, Tracy
    Dequen, Florence
    Weiss, Jessica
    Smith, Janet
    Brezden-Masley, Christine
    BREAST, 2023, 71 : S51 - S51
  • [36] Is There Still a Role for Endocrine Therapy Alone in HR+/HER2-Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies
    Cazzaniga, Marina Elena
    Verusio, Claudio
    Ciccarese, Mariangela
    Fumagalli, Alberto
    Sartori, Donata
    Valerio, Maria Rosaria
    Airoldi, Mario
    Moretti, Gabriella
    Ficorella, Corrado
    Gianni, Lorenzo
    Michelotti, Andrea
    Zambelli, Alberto
    Febbraro, Antonio
    Generali, Daniele
    Pistelli, Mirco
    Garrone, Ornella
    Musolino, Antonino
    Vici, Patrizia
    Maur, Michela
    Mentuccia, Lucia
    La Verde, Nicla
    Bianchi, Giulia Valeria
    Artale, Salvatore
    Blasi, Livio
    De Laurentiis, Michelino
    Atzori, Francesco
    Turletti, Anna
    Porpiglia, Mauro
    Santini, Daniele
    Fabi, Alessandra
    Gebbia, Vittorio
    Schirone, Alessio
    Palumbo, Raffaella
    Ferzi, Antonella
    Frassoldati, Antonio
    Scavelli, Claudio
    Clivio, Luca
    Giordano, Monica
    Donadio, Michela
    Biganzoli, Laura
    Del Mastro, Lucia
    Bisagni, Giancarlo
    Livi, Lorenzo
    Natoli, Clara
    Montemurro, Filippo
    Riccardi, Ferdinando
    Romagnoli, Emanuela
    Marchetti, Paolo
    Torri, Valter
    Pronzato, Paolo
    BREAST CARE, 2020, 15 (01) : 30 - 37
1234